Physician profile
David Hoefer
NPI 1861480592
$5,011.28
in general payments reported to CMS, 2019-2025
45 companies · $56.87 in 2025
The $56.87 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,291 · 2020: $654 · 2021: $1,102 · 2022: $1,217 · 2023: $566 · 2024: $125 · 2025: $56.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,111.21 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $578.85 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.12 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $239.95 | 2019-2022 | |
| Lilly USA, LLC | $239.35 | 2019-2023 | Mounjaro |
| Pfizer INC. | $229.30 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $205.19 | 2019-2023 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $196.80 | 2020-2023 | Trintellix |
| Glaxosmithkline, LLC. | $191.95 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company Ltd. | $128.41 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.96 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $97.07 | 2021 | |
| Vivus LLC | $94.36 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.34 | 2019-2023 | Xifaxan |
| Amgen INC. | $78.63 | 2019 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hoefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.